Abstract
“the ability of the apoA-I mimetic peptides (as demonstrated by 6F) to modulate formation or block activity of unsaturated lysophosphatidic acid in the gut appears to the relevant mechanism of action for atheroprevention.”Submitted: 5 August 2015; Accepted: 14 August 2015; Online: 23 November 2015
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
